AIM ImmunoTech Reports Q2 Loss, Topline Phase 2 Pancreatic Cancer Data Due In Q1 2027
AIM ImmunoTech reported Q2 2026 results, with net loss of about $3.8M, or $0.43/share, versus $2.8M, or $3.68/share, a year earlier. It said the final patient in its Phase 2 DURIPANC trial received Ampligen ahead of schedule. Primary endpoint analysis starts Dec 2026, topline results in Q1 2027. Cash was $9.9M.
How this was made
The 30-second read
Why it matters
The article updates the DURIPANC operational milestone (last patient dosed ahead of schedule) and provides a revised timeline for primary endpoint analysis and topline results, which can shift probability-weighting for Phase 3 planning and financing expectations. It also reports Q2 2026 financials, including cash and expense trends.
Market read
Traders get a concrete clinical milestone and a dated path to topline results, alongside updated cash and loss metrics that inform near-term risk and potential dilution expectations.
What to watch
Cash is $9.9M versus $3.8M quarterly net loss, so traders may focus on runway and potential dilution risk before Q1 2027 topline.
Background
AIM ImmunoTech is running the Phase 2 DURIPANC trial of Ampligen with AstraZeneca’s Imfinzi (durvalumab) in metastatic pancreatic cancer, and is planning a Phase 3 program contingent on results.
Ticker impact
AIM reported Q2 2026 results and said the final patient in its DURIPANC Phase 2 trial received Ampligen ahead of schedule, with topline due Q1 2027.
Likely supportive for the stock into the next clinical readout window, but magnitude may be limited given small cash balance and long-dated topline timing.
The article provides concrete trial milestone timing (last dose, primary endpoint start in Dec 2026, topline in Q1 2027) plus cash and loss figures, which can affect risk appetite and financing expectations.
Market effects
Adds incremental momentum to the oncology immunotherapy/biomarker-defined trial narrative, but does not change the broader sector outlook materially.
No clear regional market linkage beyond general biotech risk sentiment.
Limited global read-through; the key impact is company-specific clinical timing and financing risk.
Counterpoint
Despite the dosing milestone, the most decision-relevant data (topline OS and other endpoints) is still months away, so near-term price action may fade without additional interim signals.
Key entities
- companyAIM ImmunoTech Inc.
Reported Q2 2026 financial results and updated DURIPANC Phase 2 clinical trial timeline for Ampligen plus Imfinzi.
- drug_candidateAmpligen
AIM’s investigational therapy in the DURIPANC Phase 2 trial.
- clinical_trialDURIPANC
Phase 2 trial evaluating Ampligen with Imfinzi in metastatic pancreatic cancer.
- therapy_partnerImfinzi (durvalumab)
AstraZeneca’s PD-L1 therapy used in combination in DURIPANC.
